Drug pricing for a novel treatment for wet macular degeneration: using incremental cost-effectiveness ratios to ensure societal value

Sharma, Sanjay; Bakal, Jeffrey A.; Sharma, Sonam; Covert, Dave; Shah, Gaurav K.

doi:10.1016/s0008-4182(05)80079-1

Cited by 18 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, one is also concerned with evaluating newer treatments for AMD. 117 Seven of the included evaluations used outcome data from the TAP study 10,88 to estimate the effectiveness of PDT, but used data from different reporting periods (1 year, 86 2 years, 40,116 or longer 114,115 ) or from selected subgroups of patients within the trial cohort.…”

Section: 120mentioning

confidence: 99%

See 1 more Smart Citation

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation

Colquitt¹,

Jones²,

Tan³

et al. 2008

Health Technol Assess

107

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as royal colleges and NHS trusts. These sugges...

show abstract

Section: 120mentioning

confidence: 99%

“…Three studies reported on models that used trial data only. 40,86,117 Two studies reported both 'trial-based' and extrapolated analysis.…”

Section: Summary and Conclusion Of Systematic Review Of Cost-effectimentioning

confidence: 99%

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation

Colquitt¹,

Jones²,

Tan³

et al. 2008

Health Technol Assess

107

View full text Add to dashboard Cite

show abstract

“…It is unlikely that all can be fully addressed by one utility set, therefore we would encourage careful consideration when choosing utility values in decision making, an explicit critique of their applicability to the decision problem and the impact of alternative utility sets should be presented within sensitivity analysis. [67] anecortave acetate for AMD Not specified Within study (TT Trevithick et al [68] Vitamin therapy for AMD Canada Not specified Smith et al [69] Verteporfin PDT for AMD United Kingdom Brown 2000 [10] Hopley et al [70] Verteporfin PDT for nAMD …”

Section: Resultsmentioning

confidence: 99%

“…Stein et al [44] Bevacizumab and ranibizumab for newly diagnosed AMD United States HS: Brown, Side Aaberg, Bajaj, B Freeman Reeves et al [14] Verteporfin PDT for AMD United Kingdom Within study (SF Athanasakis et al [45] Ranibizumab for AMD Greece Brown 2000 [10] Brown et al [46] [47] Bevacizumab for AMD United States Modified from B Kim et al [22] PDT for AMD Korea Within study (EQ Neubauer et al [48] Ranibizumab for nAMD Germany Brown 2000 [10] Hodge et al [49] …”

Section: Chinamentioning

confidence: 99%

Health State Utility Values for Age-Related Macular Degeneration: Review and Advice

Butt

Tufail

Rubin

2016

Appl Health Econ Health Policy

View full text Add to dashboard Cite

Health state utility values are a major source of uncertainty in economic evaluations of interventions for age-related macular degeneration (AMD). This review identifies and critiques published utility values and methods for eliciting de-novo utility values in AMD. We describe how utility values have been used in health care decision making and provide guidance on the choice of utility values for future economic evaluations for AMD. Literature was searched using PubMed and health technology assessments (HTA) were searched using HTA agency websites to identify articles reporting utility values or approaches to derive utility values in AMD and articles applying utility values for use in health care decision making.s71 studies qualified for data extraction of which 22 were classified as containing utility values and/or elicitation methods relevant to AMD, while 49 were classified as using utility values in decision-making. A large number of studies have elicited utility values for AMD, although those applied to decision making have focused on a few of these. There is an appreciation of the challenges in the measurement and valuation of health states, with recent studies addressing challenges such as the insensitivity of generic health-related quality of life (HRQoL) questionnaires and utility in the worse seeing eye. We would encourage careful consideration when choosing utility values in decision making and an explicit critique of their applicability to the decision problem. Key Points for Decision Makers: There is a large body of literature describing utility values in AMD. Cost-utility analysis has been widely used to assess relative value of these interventions. A recent review of economic models comparing treatments for AMD identified 36 studies of which all but 3 reported costs per quality-adjusted life year (QALY). [2] QALYs are calculated by weighting each year of life lived using a utility score. Utility scores are anchored so that 1 is perfect health and 0 is equivalent to the state of death. Multiplying time in a health state by the health state utility value, 1 year of life lived in perfect health is equal to 1 QALY.[3]The term 'utility' in cost-utility analysis and its theory is based on von NeumannMorgenstern (vN-M) utility theory. The normative model for utility theory, the model for how a rational individual ought to behave, is that utility scores represent the strength of an individual's preference when faced with uncertainty for a given outcome, in this case a health state. A PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) scheme (Table 1) illustrates the included studies after title/abstract and full text reviews. Of the 206 studies identified, 113 studies were excluded after review of abstracts and titles. Reasons for exclusion included the topic not relating to utility, the disease not covering AMD, there being no primary data (e.g. letter or review) and the language not being English. After full text review, a further 23 studies were excluded due to the...

show abstract

“…Before this clinical trial was published, Sharma et al [10] theoretically studied the pricing per vial of anecortave acetate needed to ensure that the treatment conferred an ICER of US$50 000 per QALY compared with PDT. This model, considered a 'break-even' point from the perspective of an insurer, incorporated randomized clinical trial data, utility valuation from patients with AMD, and projected costs of the new treatment modality and the comparison (PDT).…”

Section: Search Methodologymentioning

confidence: 99%

Update on utilities and cost–utility analyses

Hollands

Sharma²

2006

Current Opinion in Ophthalmology

Self Cite

View full text Add to dashboard Cite

show abstract

Drug pricing for a novel treatment for wet macular degeneration: using incremental cost-effectiveness ratios to ensure societal value

Cited by 18 publications

References 22 publications

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation

Health State Utility Values for Age-Related Macular Degeneration: Review and Advice

Update on utilities and cost–utility analyses

Contact Info

Product

Resources

About